Morvus Technology

About:

Morvus Technology engages in the discovery, development, and commercialization of drugs and technologies in the oncology field.

Website: http://www.morvus.com

Top Investors: Fusion IP

Description:

Morvus Technology Ltd., a pharmaceutical company, engages in the discovery, development, and commercialization of drugs and technologies in the oncology field. Its clinical candidates include MTL-005, a therapy for cancers treated with conventional radiotherapy; MTL-007, a novel anti-cancer prodrug; and MTL-003, an anti-angiogenic cancer therapy. The company's research portfolio comprises MorTar platform technology that identifies new proteins and genes that share the ability to inhibit apoptosis; HAI-X, an anti-angiogenic treatment for prostate cancer; and MorGen, a novel prodrug-activating system. The company also engages in the development of anti-cancer treatments using genetic modification techniques. In addition, it offers MorAnt, an anti-parasitic drug; and MorRid, a rodenticide. Morvus Technology Ltd. was founded in 2004 and is based in Carmarthen, the United Kingdom.

Total Funding Amount:

$3.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Carmarthen, Carmarthenshire, United Kingdom

Founded Date:

2004-01-01

Contact Email:

info(AT)morvus.com

Founders:

Philip Burke

Number of Employees:

11-50

Last Funding Date:

2010-02-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai